Overview

A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM)

Status:
Completed
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the efficacy and safety of KW-0761 after intravenous injections in subjects with HTLV-1 associated myelopathy (HAM) in Japan.
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Hakko Kirin Co., Ltd
Kyowa Kirin Co., Ltd.
Treatments:
Mogamulizumab